Strengthening our Global Clinical Trial Supply Chain Capabilities in 2025

– A Year in Perspective             

As we approach the end of 2025, we are proud to reflect on a year defined by growth, innovation, and strengthened global capabilities. From regulatory milestones to strategic expansions across multiple regions, these achievements highlight our continued commitment to delivering reliable, high-quality supply chain solutions for clinical trials worldwide. Below is a look back at some of our key moments from the year.

Oximio Welcomes BARL Canada, Expanding Global Reach

Oximio’s acquisition of Bay Area Research Logistics (now Oximio BARL Canada) marked a major step in expanding our global capabilities and strengthening support for clinical trial customers across North America and beyond.

Oximio Canada Secures Medical Device Establishment License (MDEL)

Achieving the MDEL in December 2025 reflects the Canadian transition to operating under the Oximio BARL Canada structure, reinforcing the continuity of the company’s long-standing compliance. It authorises Oximio BARL Canada to import, distribute, and store medical devices, enhancing service range and ensuring compliance with Canada’s rigorous quality and safety standards.

New Saudi Arabia Depot to Open in Q1 2026

We were excited to announce the opening of a new state-of-the-art depot in Saudi Arabia, expanding our global network and reinforcing our commitment to advanced, tailored supply chain solutions in the Middle East.

Kenya Awarded Environmental Impact Assessment License

Oximio Kenya secured its NEMA EIA License, demonstrating responsible environmental stewardship and ensuring warehouse operations meet ecological protection and sustainability standards.

Kenya Achieves Customs Agent License for Greater Efficiency

The new Customs Agent License grants Oximio Kenya full control over import and export processes, reducing reliance on third parties and delivering improved efficiency and cost savings to clients across East Africa.

Türkiye Expands Cold Chain Capacity

Oximio Türkiye completed a major upgrade with the installation of a new 2°–8°C cold room, increasing cold-chain capacity by more than 50% to better support growing clinical trial activity.

Ireland Secures WDA Licence to Enhance Comparator Sourcing

The HPRA’s granting of a Wholesale Distribution Authorisation to Oximio Ireland expands comparator sourcing capabilities across Europe, strengthening support for sponsors, CROs, CDMOs, and academic partners.

Oximio Ukraine Recognised as a Critical Healthcare Partner

The Ministry of Health of Ukraine acknowledged Oximio Ukraine as a critical company during wartime, underscoring its vital role in supporting the national healthcare system during ongoing conflict.

LN₂ Storage and Handling Services Launched in Israel

In June, Oximio, Israel reached a major milestone with the launch of liquid nitrogen (LN₂) cryogenic storage and handling services, marked by the first successful domestic shipment in September. This new capability provides essential infrastructure for advanced clinical trials requiring strict cryogenic control within the country.

Putting Patients at the Heart of Every Mile

Last but certainly not least, from first mile to the last mile, we are privileged to have played our part ensuring the supply of vital medicines to patients all around the world – 365 days a year.

For all our News, Insights, Whitepapers, Webinars & Podcasts, be sure to visit our Website Resources